This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, W.-W.
Right arrow Articles by Matlashewski, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, W.-W.
Right arrow Articles by Matlashewski, G.

 Previous Article  |  Next Article 

Infection and Immunity, August 2008, p. 3777-3783, Vol. 76, No. 8
0019-9567/08/$08.00+0     doi:10.1128/IAI.01527-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Immunization with a Toll-Like Receptor 7 and/or 8 Agonist Vaccine Adjuvant Increases Protective Immunity against Leishmania major in BALB/c Mice{triangledown}

Wen-Wei Zhang and Greg Matlashewski*

Department of Microbiology and Immunology, McGill University, Montreal, Quebec H3A 2B4, Canada

Received 16 November 2007/ Returned for modification 4 January 2008/ Accepted 7 May 2008

Activation of Toll-like receptors (TLRs) on antigen-presenting cells of the innate immune system initiates, amplifies, and directs the antigen-specific acquired immune response. Ligands that stimulate TLRs therefore represent potential vaccine adjuvants. In the present study, we determined whether imiquimod and its related compound R848, which are TLR7 and/or TLR8 agonists, represent potential vaccine adjuvants when delivered topically, subcutaneously, or intramuscularly. Using the Leishmania major infection model in BALB/c mice, vaccination with crude Leishmania antigen was not protective against subsequent challenge infection unless it was administered with R848 or a topical application of imiquimod containing cream on the skin. Subcutaneous vaccination with these adjuvants mediated a TH1 response against L. major antigen, which appeared to suppress the TH2 response following a challenge infection. Protective immunity was generated following subcutaneous vaccination but not intramuscular vaccination. These observations suggest that topically administered imiquimod or subcutaneously injected R848 represent potential vaccine adjuvants to enhance the TH1 response, which can be used with existing or new vaccine formulations.

* Corresponding author. Mailing address: Department of Microbiology and Immunology, 3775 University Street, McGill University, Montreal, Quebec H2A 2B4, Canada. Phone: (514) 398-3914. Fax: (514) 398-7052. E-mail: greg.matlashewski{at}mcgill.ca

{triangledown} Published ahead of print on 12 May 2008.

Editor: J. F. Urban, Jr.

Infection and Immunity, August 2008, p. 3777-3783, Vol. 76, No. 8
0019-9567/08/$08.00+0     doi:10.1128/IAI.01527-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Othoro, C., Johnston, D., Lee, R., Soverow, J., Bystryn, J.-C., Nardin, E. (2009). Enhanced Immunogenicity of Plasmodium falciparum Peptide Vaccines Using a Topical Adjuvant Containing a Potent Synthetic Toll-Like Receptor 7 Agonist, Imiquimod. Infect. Immun. 77: 739-748 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»